Primary surgical cytoreduction in advanced ovarian cancer: An outcome analysis within the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) Group
- PMID: 26825616
- DOI: 10.1016/j.ygyno.2016.01.025
Primary surgical cytoreduction in advanced ovarian cancer: An outcome analysis within the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) Group
Abstract
Objective: To draw a reliable picture of the surgical management of advanced ovarian cancer (AOC) within the MITO Group, trying to correlate the disease extent at presentation, the category of center, and surgical outcome.
Methods: Three tertiary referral centers for gynecologic oncology and four non-oncologic referral gynecologic surgical centers, participated in the project. A questionnaire was adopted to register perioperative data on AOCs (FIGO Stage IIICIV) consecutively operated on for a period of 12months.
Results: A total of 205 patients were registered into the study: 140 and 65 were recruited in oncological referral centers and non-referral centers, respectively. Following a multivariate analysis, the Eisenkop score and the category of center resulted the most potent predictors of complete surgical cytoreduction followed by PCI, preoperative CA125, and ASA score. Complete surgical cytoreduction was associated with oncological referral centers (60% vs 24.6%, p<0.001). The proportion of patients undergoing additional surgical procedures was significantly different comparing the two categories of centers (at least one additional procedure was performed in 81.4% vs 50.8% in oncological referral centers compared to the others, p<0.001). Despite the more aggressive surgery performed in oncological referral centers, the perioperative outcome measures were not significantly different in the two groups.
Conclusions: The chance of obtaining a complete cytoreduction mainly depends on patient characteristics, tumor spread, and quality of treatment. The latter is amenable for direct influence, and therefore, seems to be of utmost importance when considering efforts aiming at improvement in the outcome of this disease.
Copyright © 2016 Elsevier Inc. All rights reserved.
Similar articles
-
Use of complex surgical procedures, patterns of tumor spread, and CA-125 predicts a risk of incomplete cytoreduction: a Korean Gynecologic Oncology Group study (KGOG-3022).Gynecol Oncol. 2013 Nov;131(2):336-40. doi: 10.1016/j.ygyno.2013.07.110. Epub 2013 Aug 13. Gynecol Oncol. 2013. PMID: 23954903
-
Prognostic value of peritoneal cancer index in primary advanced ovarian cancer.Eur J Surg Oncol. 2018 Jan;44(1):163-169. doi: 10.1016/j.ejso.2017.11.003. Epub 2017 Nov 23. Eur J Surg Oncol. 2018. PMID: 29198495
-
The limits of aggressive surgical cytoreduction.Gynecol Oncol. 2018 Aug;150(2):205-206. doi: 10.1016/j.ygyno.2018.07.006. Gynecol Oncol. 2018. PMID: 30025830 No abstract available.
-
Role of aggressive surgical cytoreduction in advanced ovarian cancer.J Gynecol Oncol. 2015 Oct;26(4):336-42. doi: 10.3802/jgo.2015.26.4.336. Epub 2015 Jul 17. J Gynecol Oncol. 2015. PMID: 26197773 Free PMC article. Review.
-
[Effectiveness of "threshold" in the management of ovarian cancer: A review of the literature].Bull Cancer. 2016 Jun;103(6):513-23. doi: 10.1016/j.bulcan.2016.03.010. Epub 2016 May 26. Bull Cancer. 2016. PMID: 27238445 Review. French.
Cited by
-
An Italian National Survey on Ovarian Cancer Treatment at first diagnosis. There's None so Deaf as those who will not Hear.J Cancer. 2021 May 27;12(15):4443-4454. doi: 10.7150/jca.57894. eCollection 2021. J Cancer. 2021. PMID: 34149908 Free PMC article.
-
Honeycomb-like Structured Film, a Novel Therapeutic Device, Suppresses Tumor Growth in an In Vivo Ovarian Cancer Model.Cancers (Basel). 2022 Dec 30;15(1):237. doi: 10.3390/cancers15010237. Cancers (Basel). 2022. PMID: 36612230 Free PMC article.
-
Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.Cochrane Database Syst Rev. 2022 Sep 26;9(9):CD015048. doi: 10.1002/14651858.CD015048.pub2. Cochrane Database Syst Rev. 2022. PMID: 36161421 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous